IOL Chemicals and Pharmaceuticals stock is up 322 percent for the year. However, in a report by Spark Capital on the API industry, they said that they do not think the API growth in Q1 is sustainable for a long period. They added that Q1 performance cannot be extrapolated for the remaining quarters.

To discuss the company’s outlook going ahead, CNBC-TV18 spoke to Vijay Garg, Joint MD of IOL Chemicals and Pharmaceuticals.

Watch the video for more.